CEO Interview

AI SummaryClose X

Thalia Therapeutics plc announced the release of a video interview with its CEO discussing the company's differentiated approach to developing next-generation RNA therapeutics, particularly a long-acting preclinical candidate for cardiovascular disease that targets both PCSK9 and Lp(a). The interview highlights Thalia's positioning in the expanding RNA therapeutics market and its proprietary delivery technology, Nuvec®, which aims to overcome RNA delivery challenges. The company's focus on genetically targeted approaches for cardiovascular disease is further underscored by recent research in The New England Journal of Medicine.

Disclaimer*

UK 100

Latest directors dealings